Selection of 3 products from
£0.49 to £1.49
Upcard is a recently developed type of diuretic (water tablet). It helps to expel an excessive build up of fluid in the body and is generally used in cases of congestive heart failure, or where oedema has developed. The active ingredient is torasemide and is believed to produce a better outcome than frusemide which has been used for a long time for the same sort of purpose.
All prices include VAT where applicable.
UpCard 0.75 mg tablets: oblong white to off-white tablets with 1 break-line on each side. The tablets can be divided into equal halves.
UpCard 3 mg and 7.5 mg tablets: oblong white to off-white tablets with 3 break-lines on each side. The tablets can be divided into equal quarters.
For treatment of clinical signs, including oedema and effusion, related to congestive heart failure.
UpCard tablets can be administered with or without food.
The recommended dose of torasemide is 0.1 to 0.6 mg per kg bodyweight, once daily. The majority of dogs are stabilised at a dose of torasemide less than or equal to 0.3 mg per kg bodyweight, once daily. The dosage should be titrated to maintain patient comfort with attention to renal function and electrolytes status. If the level of diuresis requires alteration, the dose may be increased or decreased within the recommended dose range by increments of 0.1 mg/kg bodyweight. Once signs of congestive heart failure have been controlled and the patient is stable, if long term diuretic therapy with this product is required it should be continued at the lowest effective dose.
Frequent re-examinations of the dog will enhance the establishment of an appropriate diuretic dose.
The daily schedule of administration can be timed to control the period of micturition according to need.
Do not use in case of renal failure.
Do not use in case of severe dehydration, hypovolaemia or hypotension.
Do not use concomitantly with other loop diuretics.
Do not use in case of hypersensitivity to the active substance or to any of the excipients.
In dogs presenting in acute crisis with pulmonary oedema, pleural effusion and/or ascites requiring emergency treatment, the use of injectable drugs should be considered first before commencing oral diuretic therapy.
Renal function, hydration status and serum electrolytes status should be monitored:
- At treatment initiation
- from 24 hours to 48 hours after treatment initiation
- from 24 hours to 48 hours after dose change
- In case of adverse events.
While the animal is on treatment, these parameters should be monitored at very regular intervals according to the benefit-risk assessment performed by the responsible veterinarian.
Torasemide should be used with caution in cases of diabetes mellitus, and in dogs with previously prescribed high doses of an alternative loop diuretic. In dogs with pre-existing electrolyte and/or water imbalance, this should be corrected prior to treatment with torasemide.
Torasemide treatment should not be initiated in dogs already clinically stable on an alternative diuretic for treatment of the signs of congestive heart failure, except where this has been justified taking into account the risk of de-stabilising the clinical condition and of adverse reactions as indicated below.
People with known hypersensitivity to torasemide or other sulphonamides should administer the veterinary medicinal product with caution.
This product may cause increased urination and/or gastrointestinal disturbances if ingested.
Keep tablets in the blister packs until required, and keep the blisters in the outer carton.
In case of accidental ingestion, particularly in the case of children, seek medical advice immediately and show the package leaflet or the label to the physician.
Increase in renal blood parameters and renal insufficiency are very commonly observed during treatment.
As a result of the diuretic action of torasemide, haemoconcentration and, very commonly, polyuria and/or polydipsia are observed.
In cases of prolonged treatment, electrolyte deficiency (including hypokalaemia, hypochloraemia, hypomagnesaemia) and dehydration may occur.
Gastrointestinal signs which include emesis, reduced or absent faeces and, in rare cases, soft faeces may be observed. Occurrence of soft faeces is transient, mild, and does not necessitate the withdrawal of the treatment.
Erythema of the inner pinnae may be observed.
The frequency of adverse reactions is defined using the following convention:
- very common (more than 1 in 10 animals displaying adverse reaction(s) during the course of one treatment)
- common (more than 1 but less than 10 animals in 100 animals)
- uncommon (more than 1 but less than 10 animals in 1,000 animals)
- rare (more than 1 but less than 10 animals in 10,000 animals)
- very rare (less than 1 animal in 10,000 animals, including isolated reports).
The safety of the veterinary medicinal product has not been established during pregnancy or lactation. The use of UpCard is not recommended during pregnancy, lactation and in breeding animals.
Co-administration of loop diuretics and NSAIDs can result in a decreased natriuretic response.
Concomitant use with veterinary medicinal products affecting electrolyte balance (corticosteroids, amphotericin B, cardiac glycosides, other diuretics) requires careful monitoring.
Concurrent use of drugs that increase the risk of renal injury or renal insufficiency should be avoided.
Concomitant use with aminoglycosides or cephalosporins may increase the risk of nephrotoxicity and ototoxicity.
Torasemide may increase the risk of sulfonamide allergy.
Torasemide can reduce the renal excretion of salicylates, leading to an increased risk of toxicity.
Care should be exercised when administering torasemide with other highly plasma protein bound drugs. Since protein binding facilitates the renal secretion of torasemide, a decrease in binding due to displacement by another drug may be a cause of diuretic resistance.
Concomitant administration of torasemide with other drugs metabolised by cytochrome P450 families 3A4 (e.g.: enalapril, buprenorphine, doxycycline, cyclosporine) and 2E1 (isoflurane, sevoflurane, theophylline) may decrease their clearance from the systemic circulation.
The effect of antihypertensive drugs, especially angiotensin converting enzyme (ACE)-inhibitors, may be potentiated when co-administered with torasemide.
When used in combination with cardiac treatments (e.g. ACE-inhibitors, digoxin), the dose regimen may need to be modified depending upon the animal’s response to therapy.
Doses greater than 0.8 mg/kg/day have not been evaluated in the target animal safety or controlled clinical studies. However, it is anticipated that overdose increases the risk of dehydration, electrolyte imbalance, renal insufficiency, anorexia, weight loss and cardiovascular collapse.
Treatment should be symptomatic.
Any remaining tablet part should be discarded after 7 days.
This veterinary medicinal product does not require any special storage conditions.
Any part tablet should be stored in the blister pack or in a closed container for a maximum of 7 days.
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with local requirements.
Blister pack containing 10 tablets
All strengths are available in the following pack sizes:
Pack sizes of 30 or 100 tablets.
Not all pack sizes may be marketed.
In dogs, after a single intravenous dose at 0.1 mg/kg, the total body clearance was 0.017 L/h∙kg, the volume of distribution was 0.14 L/kg and the terminal half-life was 7.0 hours. After a single oral dose of 0.1 mg/kg, the oral absolute bioavailability corresponded to about 90%. The oral absorption was fast with mean Tmax at 0.93 hours after administration of 0.1 mg/kg. The maximum plasma concentrations Cmax corresponded to 1.1 µg/mL after a single oral dose of 0.1 mg/kg and to 19 µg/mL after a single oral dose of 1.6 mg/kg. The AUCinf corresponded to 6.3 µg∙h/mL after a single oral dose of 0.1mg/kg and to 153.6 µg∙h/mL after a single oral dose of 1.6 mg/kg. The plasma protein binding was > 98%. A large proportion of the dose (between 61% and 70%) is excreted in the urine as unchanged parent drug. Two metabolites (a dealkylated and a hydroxylated metabolite) were also identified in urine. The parent drug is metabolised by the hepatic cytochrome P450 families 3A4 and 2E1, and to a lesser extent by 2C9. Dose proportionality for Cmax and AUCinf was demonstrated between 0.2 and 1.6 mg/kg. Feeding significantly increased torasemide AUClast by 36% on average and slightly delayed Tmax but no significant impact on Cmax was detected. After repeated administration to dogs at 0.2 mg/kg daily for 14 days, no plasma accumulation of torasemide was detected.
Under almost all products on our website is an Estimated dispatch time, check this for a delivery prediction specific to the item you are looking to purchase. These badges are updated live based on the stock levels we have and also those of our suppliers - so are usually very accurate, but cannot be guaranteed. In more general terms, we aim to dispatch all orders within 1 working day of receiving payment (and a prescription if required). If we cannot do so within 3 working days we will contact you by email.
For UK delivery, we charge the following:
Prices quoted are for delivery to all parts of mainland UK except certain Scottish postcodes (where the price is higher for items sent by courier. Delivery of food abroad (including Channel Islands, N. Ireland and other islands around the UK) is charged at a higher price and free delivery is not available. Temperature controlled products, such as Insulin, are also not always subject to the standard and/or free delivery options.
For full information on our delivery charges, including prices on heavy deliveries to Scotland and abroad, see our delivery information page.
We can deliver most items to all around the world, but prices do vary. The majority of light weight orders (less than 1.5kg) can be delivered for a flat rate of £10. For an accurate estimate of the delivery charge, please put the items you require in your basket and use the "Estimate Delivery" system on the shopping basket page (you only need to enter your country and postal/zip code) for a quick quote. For deliveries to the USA you may need to go to the checkout page and enter your full address to get a quote (as some services need your state in order to quote too). For more information on international deliveries, please see our delivery information page.
Due to air freight restrictions aerosols cannot ever be sent abroad by Royal Mail. We appreciate your understanding.
Some products, such as insulin and frozen food, need to be delivered in insulated packaging to prevent them from getting too warm (or too cold) during transit from us to you. Purchasing any of these items in your order will result in a £1.99 charge being added to the total to cover the high cost of the insulated packaging materials. You only pay the £1.99 once per order, regardless of how many temperature controlled items you purchase in that order.
Please call us as soon as possible if you need to amend or cancel an order on 01582 842096. If your order has been processed for dispatch we will be unable to cancel or amend the order. You will however be able to return your product for a full refund*.
To return an item, you must contact us by phone or email to arrange this BEFORE posting any product back to us. We will explain the process at this stage for you.
*For full details on returns, see our terms and conditions page.
Below are some recent questions we've received regarding Upcard, including answers from our team.
My vet has prescribed Up card 0.75 mg 1 tablet daily for my cat with congestive heart Failure and CHM. I've read it is specifically for dogs only, is this safe to use please?
Yes, Upcard is safe to use in cats. It is licensed only for dogs but vets can prescribe it off license for use in cats too.